NCT05106777

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

A Multi-center, Open Label Study of Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 14 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.

Detailed description

The study population is patients with advanced osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy treatment. Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle. Investigators will evaluate the clinical tumor response to Surufatinib, and if investigators determine that the patient can benefit from the continuation of treatment, the patient will continue the Surufatinib treatment. The duration of study will be 2 years. At the time of study completion, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with Surufatinib with the agreement of the sponsor.

Conditions

• Sarcoma

Interventions

Type	Name	Description
DRUG	Surufatinib	Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.

Timeline

• Start date: 2021-12-10
• Primary completion: 2023-12-10
• Completion: 2023-12-10
• First posted: 2021-11-04
• Last updated: 2023-04-12

Locations

1 site across 1 country: China